Pretreatment predictive factors for primary resistance to nivolumab plus ipilimumab in advanced renal cell carcinoma: a multicenter collaborative study
Sarcomatoid differentiation on pretreatment biopsy or elevated serum LDH before treatment initiation may predict primary resistance to nivolumab plus ipilimumab therapy in patients with advanced RCC. Alternative regimens should be considered in such cases, particularly for patients who are likely to experience rapid disease progression or for whom the occurrence of P-res is not clinically acceptable.
Authors
- Toru Kanno (ORCID: https://orcid.org/0000-0001-9445-4035)
- Yasumasa Shichiri
- Takayuki Goto (ORCID: https://orcid.org/0000-0002-6068-2897)
- Yuki Kita (ORCID: https://orcid.org/0000-0002-6942-9695)
- Satoshi Ishitoya (ORCID: https://orcid.org/0000-0001-8417-2253)
- Kimihiko Masui (ORCID: https://orcid.org/0000-0002-7841-1104)
- Atsuro Sawada (ORCID: https://orcid.org/0000-0003-4833-1709)
- Satoru Masui
- Takahiro Yamaguchi (ORCID: https://orcid.org/0000-0001-5167-0854)
- Sojun Kanamaru
- Takehiko Segawa
- N. Ito
- Takashi Kobayashi
- Toshinari Yamasaki
- Takayuki Sumiyoshi
- Naoki Hayata
- Koji Yoshimura
- Hiroyuki Onishi
- Kazuhiro Okumura
Institutions
- University of Miyazaki (JP)
- Mie University (JP)
- Kyoto University (JP)
- Tenri Hospital (JP)
- Kyoto Medical Center (JP)
- Kurashiki Central Hospital (JP)
- Kyoto City Hospital (JP)
- Kobe City Nishi-Kobe Medical Center (JP)
- Otsu Red Cross Hospital (JP)
- Shizuoka General Hospital (JP)
- Osaka Red Cross Hospital (JP)
- Japanese Red Cross Society Wakayama Medical Center (JP)
- Kobe City Medical Center General Hospital (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1093/jjco/hyaf197
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00